Results 211 to 220 of about 5,395,673 (305)

An Activity‐Reinforced P‐Modified Single‐Atom Cu Nanozyme Potentiates IDO Blockade‐Induced Tumor Radiotherapy

Advanced Science, EarlyView.
A phosphorus‐modified single‐atom copper nanozyme delivering the IDO1 inhibitor 1‐methyl‐tryptophan enhances breast cancer radioimmunotherapy by simultaneously relieving hypoxia and inducing immunogenic cell death through dual enzyme activities while blocking tryptophan metabolism to suppress regulatory T cell function.
Wei Zhao, Songliu Hu, Zhanggui Wang, Liqun Wang, Liming Zhang, Qi Li, Hua Tang, Yang Zhong, Zhongxian Zhang, Kelong Fan, Shipeng Ning, Xiyun Yan   +11 more
wiley   +1 more source

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer.

JAMA Oncol, 2018
Pezzi TA, Schwartz DL, Mohamed ASR, Welsh JW, Komaki RU, Hahn SM, Sepesi B, Pezzi CM, Fuller CD, Chun SG.   +9 more
europepmc   +1 more source

Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence? [PDF]

J Radiat Res, 2017
Jeremic B, Casas F, Dubinsky P, Gomez-Caamano A, Cihoric N, Videtic G, Latinovic M.   +6 more
europepmc   +1 more source

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

Advanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale, Marie Celine Lefevre, Alessio Carmignani, Maria Cristina Ceccarelli, Matteo Battaglini, Attilio Marino, Gianni Ciofani   +6 more
wiley   +1 more source

Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer. [PDF]

Clin Lung Cancer, 2017
Zaki M, Dominello M, Dyson G, Gadgeel S, Wozniak A, Miller S, Paximadis P.   +6 more
europepmc   +1 more source

Engineering Microbial Particles for Next‐Generation Biomedical Platforms

Advanced Science, EarlyView.
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li, Yunjie Lu, Ziyan Huang, Jianjiang Chen, Yanbin Liu, Lei Qin, Chao Wang, Yumin Wu   +7 more
wiley   +1 more source

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. [PDF]

Front Oncol, 2016
Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG.   +4 more
europepmc   +1 more source

Combined modality therapy: Clinical and laboratory aspects [PDF]

British Journal of Cancer, 1982
openaire   +2 more sources

Multidimensional and Multifunctional Laser‐Induced Graphene (LIG) for Point‐of‐Care and Wearable Biosensing, Theranostics, and Bioactive Interfaces Toward Personalized Healthcare and Regenerative Medicine

Advanced Science, EarlyView.
Multidimensional laser‐induced graphene (LIG) spanning from 0D to 3D architectures is comprehensively reviewed for multifunctional biomedical platforms, including biosensing, theranostics, and bioactive interface applications, which highlights its potentials for point‐of‐care diagnostics, wearable health monitoring, smart drug delivery, and tissue ...
Li Zhang, Yurou Yuan, Xiaohong Ding, Wing Cheung Mak   +3 more
wiley   +1 more source

Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

JAMA Oncol, 2019
Jhawar SR, Rivera-Núñez Z, Drachtman R, Cole PD, Hoppe BS, Parikh RR.   +5 more
europepmc   +1 more source